Genomic and Transcriptomic Profiling Reveals Distinct Subsets Associated with Outcomes in Mantle Cell Lymphoma

套细胞淋巴瘤 生物 癌症的体细胞进化 遗传学 外显子组测序 外显子组 ARID1A型 癌症研究
作者
Yuting Yan,Shuhua Yi,Meiling Jin,Yi Wang,Ying Yu,Wang Jun,Dehui Zou,Tingyu Wang,Zhen Yu,Lanting Liu,Rui Cui,Wei Liu,Ryu Lv,Weiwei Sui,Wenyang Huang,Xiong Wenjie,Huijun Wang,Qi Sun,Mu Hao,Jianxiang Wang,Cheng Tao,Lugui Qiu,Lili Wang
出处
期刊:Blood [Elsevier BV]
卷期号:136: 28-29 被引量:2
标识
DOI:10.1182/blood-2020-139955
摘要

Introduction Mantle cell lymphoma (MCL) is a rare subtype of aggressive non-Hodgkin's lymphoma in which the genomic factors determining the clinical behavior are not fully understood. The genetic heterogeneity in MCL motivates us to characterize the genetic landscape, to define pattern of clonal evolution, and to determine molecular subgroups. Methods We performed whole-exome sequencing on 152 DNA samples derived from 134 MCL patients, which includes 123 untreated and 11 relapsed patients, and 16 with longitudinal samples. 95 patients received high dose cytarabine-based immunochemotherapy from BDH-MCL01 clinical trial (NCT02858804). 48 samples have matched RNA sequencing data for which 42 from untreated and 6 from relapsed patients. We used GATK, MutSig2CV, and GISTIC2.0 to identify driver genetic lesions, applied MutationalPatterns to define mutational signatures, and utilized ABSOLUTE and PhylogicNDT to determine pattern of clonal evolution. We applied NNMF consensus clustering to identify subgroups and evaluated association between genomic features and clinical outcomes. Results The median non-silent mutational burden was 29 per sample (range 8-72). 34 recurrently mutated genes were identified, containing previously reported driver mutations (TP53, ATM, CCND1, KMT2D, NSD2, SMARCA4, ARID1A, NOTCH1, NOTCH2, BIRC3, TRAF2, UBR5) and novel mutations (SP140, SVEP1, LRP1B, LRP2, PCDH10). 7 copy number gain and 13 loss regions were detected as recurrent somatic copy number alterations (frequency>10%, q We defined the clonal status of genetic lesions and pattern of clonal evolution. Del(11q22) and del(9p) tend to be clonal while mutations in NSD2, LRP1B, CTNNA2 were more likely to be subclonal (q 0.5), 4 with modest evolution (0.2 ≤ CCF change ≤ 0.5), 1 without evolution (CCF change We classified MCL into four subsets based on genetic lesions, each with distinct gene expression profile and clinical behavior (Fig C, D). Cluster 1 (C1) and cluster 2-4 (C2-4) were associated with indolent and aggressive types of MCL. Consistent with different cellular origins for two types of MCL, C1 and C2-4 were enriched for gene expression signatures of memory and CCR6 negative light zone B cells, respectively. C1 featured mutated IGHV, CCND1 mutation, amp(11q13) and active BCR signaling. C2 was enriched with del (11q22), del (1p21), ATM mutation and had upregulation of genes involved in the NF-kB and DNA repair pathways while C3 was characterized by mutations in SP140, NOTCH1 and NSD2 and downregulation of gene expression in the NF-kB, BCR signaling, MYC and inflammatory pathways. Interestingly, C4 had the highest incidence of blastoid or pleomorphic MCL (23.7%, p=0.016) and harbored del(17p), del(13q), del(9p) and mutations in TP53 and TRAF2. This cluster carried enrichment of MYC pathway activation and hyperproliferation signatures. These unique gene expression signatures indicated that coordinate genomic factors captured biologic heterogeneity. Importantly, patients in these four clusters had distinct outcomes with median PFS of not reached for C1, 41.2 months for C2, 30.7 months for C3, and 16.1 months for C4 (log rank, p Conclusion Our study provides a portrait of the MCL genetic landscape, uncovers pattern of clonal evolution in MCL, classifies patients with genetic features, links the cluster with gene expression and clinical outcome. The outcome-associated genetic signatures will guide the development of therapies in patients with the greatest need. Download : Download high-res image (1MB) Download : Download full-size image Figure . Disclosures No relevant conflicts of interest to declare.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
清辉影的应助被XPR采纳,获得10
1秒前
小浅浅发布了新的文献求助10
1秒前
2秒前
科目三的应助被yuyuhong采纳,获得10
2秒前
麻瓜完成签到,获得积分10
2秒前
叫我老贾就好了完成签到,获得积分10
3秒前
丘比特的应助被科研通管家采纳,获得10
3秒前
田様的应助被科研通管家采纳,获得10
4秒前
英姑的应助被科研通管家采纳,获得10
4秒前
4秒前
慕青的应助被科研通管家采纳,获得10
4秒前
4秒前
4秒前
852的应助被科研通管家采纳,获得10
4秒前
velsaber的应助被科研通管家采纳,获得10
4秒前
打打的应助被科研通管家采纳,获得10
5秒前
思源的应助被科研通管家采纳,获得10
5秒前
彭于晏的应助被科研通管家采纳,获得10
5秒前
我是老大的应助被科研通管家采纳,获得10
5秒前
orixero的应助被科研通管家采纳,获得10
5秒前
安彩青完成签到 ,获得积分10
5秒前
Maestro_S的应助被科研通管家采纳,获得10
5秒前
LA完成签到,获得积分10
5秒前
情怀的应助被荣荣采纳,获得10
6秒前
Sean发布了新的文献求助10
7秒前
薛广苏发布了新的文献求助10
7秒前
美味又健康完成签到 ,获得积分10
8秒前
forktail完成签到,获得积分10
10秒前
大模型的应助被乔治采纳,获得10
10秒前
海盐芝士完成签到,获得积分10
11秒前
hurys的应助被麻瓜采纳,获得50
11秒前
shgong发布了新的文献求助20
12秒前
852的应助被麻瓜采纳,获得10
12秒前
wenhao完成签到 ,获得积分10
12秒前
Akim的应助被coco采纳,获得10
13秒前
植柏完成签到,获得积分10
13秒前
数学情缘完成签到,获得积分10
13秒前
14秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181823
求助须知:如何正确求助?哪些是违规求助? 9571511
关于积分的说明 21818391
捐赠科研通 7778076
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479614